AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35984478 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (POC group)
Number of subjects: 185
Study 35507912 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination with 5, 10, and 20 μg hepatitis B vaccines or 5 μg hepatitis A and B (HAB) combination vaccine with a 0-1-6-month schedule (schedule 2 group)
Number of subjects: 102
Study 35507912 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster vaccination for anti-HBs positive subjects (schedule 1 group)
Number of subjects: 102
Study 32949374 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus lenalidomide and dexamethasone (Rd)
Number of subjects: 52
Study 32949374 — intervention group
Group type: COMPARATOR
Intervention: Rd alone
Number of subjects: 52
Study 35977863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks for 52 weeks
Number of subjects: 97
Study 35977863 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 35977863 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg
Number of subjects: 97
Study 33509275 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of REMAP-COVID trial procedures into routine care processes
Number of subjects: 0
Study 33509275 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote consent and enrollment
Number of subjects: 0
Study 33509275 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination with the central institutional review board
Number of subjects: 0
Study 33509275 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol adherence, adverse event monitoring, and data collection
Number of subjects: 0
Study 33509275 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishment of a centralized institutional process
Number of subjects: 0
Study 33008287 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC genes under salt stress
Number of subjects: 160
Study 33008287 — intervention group
Group type: EXPERIMENTAL
Intervention: NAC genes under drought stress
Number of subjects: 160
Study 33008287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultivated peanut NAC genes under both stresses
Number of subjects: 160
Study 33008287 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-qPCR analysis of NAC genes
Number of subjects: 160
Study 35620884 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 90
Study 35620884 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's heartbeat sounds
Number of subjects: 90
Study 35620884 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk odour
Number of subjects: 90
Study 33894146 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg
Number of subjects: 119
Study 33894146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 32314514 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe extract treatment for 4 weeks
Number of subjects: 160
Study 32314514 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (inulin) for 4 weeks
Number of subjects: 160
Study 32314514 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe treatment responders (n = 33, 39%)
Number of subjects: 160
Study 32314514 — intervention group
Group type: COMPARATOR
Intervention: Control treatment responders (n = 34, 45%)
Number of subjects: 160
Study 35821950 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative educational video
Number of subjects: 183
Study 35821950 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative educational video and postoperative acceptance and commitment therapy (ACT)
Number of subjects: 183
Study 35821950 — intervention group
Group type: COMPARATOR
Intervention: Control group, no perioperative counseling
Number of subjects: 183
Study 34108673 — intervention group
Group type: EXPERIMENTAL
Intervention: AHSCT
Number of subjects: 49
Study 34108673 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 49
Study 32334553 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered drug intake supported by a family member
Number of subjects: 385
Study 32334553 — intervention group
Group type: COMPARATOR
Intervention: Clinical DOT at Outpatient-TB-centres
Number of subjects: 385
Study 33244615 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic ultrasound (US) for managing tube thoracostomy (TT)
Number of subjects: 61
Study 33244615 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray (CXR) for managing tube thoracostomy (TT)
Number of subjects: 61
Study 33356422 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan and cetuximab with vemurafenib (960 mg PO twice daily)
Number of subjects: 106
Study 33356422 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan and cetuximab without vemurafenib
Number of subjects: 106
Study 33356422 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan and cetuximab with vemurafenib
Number of subjects: 106
Study 32081989 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) using Skylights headset
Number of subjects: 50
Study 32081989 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no VR)
Number of subjects: 50
Study 33942338 — intervention group
Group type: EXPERIMENTAL
Intervention: Mann‐Whitney probability estimation procedures
Number of subjects: 0
Study 33942338 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidence interval estimation procedures
Number of subjects: 0
Study 33942338 — intervention group
Group type: EXPERIMENTAL
Intervention: Variance estimators
Number of subjects: 0
Study 33942338 — intervention group
Group type: EXPERIMENTAL
Intervention: Logit and inverse hyperbolic sine transformations
Number of subjects: 0
Study 33942338 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomization trials
Number of subjects: 0
Study 33243018 — intervention group
Group type: EXPERIMENTAL
Intervention: Quxie capsule (QX) treatment
Number of subjects: 34
Study 33243018 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 34
Study 35985551 — intervention group
Group type: EXPERIMENTAL
Intervention: Video visits
Number of subjects: 653
Study 35985551 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person visits
Number of subjects: 653
Study 34470831 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose (100 mg biweekly, total 2 g over 40 weeks)
Number of subjects: 142
Study 34470831 — intervention group
Group type: COMPARATOR
Intervention: Ferric carboxymaltose (500 mg every 10 weeks, total 2 g over 40 weeks)
Number of subjects: 142
Study 34470831 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agent use
Number of subjects: 142
Study 35766224 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotersen
Number of subjects: 0
Study 35766224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35766224 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotersen (greatest-benefit subgroup)
Number of subjects: 0
Study 35766224 — intervention group
Group type: COMPARATOR
Intervention: Placebo (greatest-benefit subgroup)
Number of subjects: 0
Study 33529612 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-based home program
Number of subjects: 75
Study 33529612 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-based home program
Number of subjects: 75
Study 33529612 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study 33774620 — intervention group
Group type: EXPERIMENTAL
Intervention: Water supplementation in habitual low drinkers with high copeptin
Number of subjects: 0
Study 33774620 — intervention group
Group type: EXPERIMENTAL
Intervention: Water supplementation for 1 year
Number of subjects: 0
Study 34965603 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable nasal implant
Number of subjects: 111
Study 32318809 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg daily for 7 days
Number of subjects: 26
Study 32318809 — intervention group
Group type: COMPARATOR
Intervention: Fedratinib 500 mg single dose
Number of subjects: 26
Study 36227659 — intervention group
Group type: EXPERIMENTAL
Intervention: mPEG-HA-Pt treatment
Number of subjects: 76
Study 36227659 — intervention group
Group type: COMPARATOR
Intervention: Traditional chemotherapy (control)
Number of subjects: 76
Study 34510143 — intervention group
Group type: EXPERIMENTAL
Intervention: Prismatic RGP contact lenses with a base-down prism of 1.6 prism diopters
Number of subjects: 17
Study 34510143 — intervention group
Group type: COMPARATOR
Intervention: Standard rigid-gas-permeable contact lenses
Number of subjects: 17
Study 34510143 — intervention group
Group type: EXPERIMENTAL
Intervention: Both contact lens designs (standard and prismatic)
Number of subjects: 17
Study 32400321 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-help intervention
Number of subjects: 60
Study 35114286 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant coffee with 3 mg/kg caffeine
Number of subjects: 33
Study 35114286 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant coffee with 6 mg/kg caffeine
Number of subjects: 33
Study 35114286 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 33
Study 33122028 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 64
Study 33122028 — intervention group
Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 64
Study 33747510 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligelizumab (240 mg q2w)
Number of subjects: 471
Study 33747510 — intervention group
Group type: COMPARATOR
Intervention: Omalizumab
Number of subjects: 471
Study 33747510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 471
Study 36315560 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 152
Study 36315560 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 152
Study 33779577 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic escitalopram
Number of subjects: 390
Study 33779577 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary escitalopram (Lexapro)
Number of subjects: 390
Study 33779577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 35727573 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic (10 billion CFUs daily during antibiotic treatment and for 7 days after)
Number of subjects: 350
Study 35727573 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study 35727573 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic
Number of subjects: 350
Study 33125674 — intervention group
Group type: EXPERIMENTAL
Intervention: Globalagliatin (high-dose)
Number of subjects: 24
Study 33125674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 36096108 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis + Hemoperfusion (HD + HP)
Number of subjects: 150
Study 36096108 — intervention group
Group type: COMPARATOR
Intervention: Simple Hemodialysis (HD)
Number of subjects: 150
Study 33210331 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa (AN)
Number of subjects: 10
Study 33210331 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN)
Number of subjects: 10
Study 33210331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no eating disorder)
Number of subjects: 10
Study 35762272 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 60
Study 35762272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32124728 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg/serotype/dose adjuvanted with aluminum
Number of subjects: 100
Study 32124728 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg/serotype/dose adjuvanted with AS01E
Number of subjects: 100
Study 32124728 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 μg/serotype/dose adjuvanted with AS03B
Number of subjects: 100
Study 32124728 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 μg/serotype/dose adjuvanted with aluminum
Number of subjects: 100
Study 32124728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 36351688 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate radiographer (IR) reporting
Number of subjects: 8682
Study 36351688 — intervention group
Group type: COMPARATOR
Intervention: Standard radiographer (SR) reporting
Number of subjects: 8682
Study 33664127 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (paclitaxel 175 mg/m2 plus cisplatin 50 mg/m2 or carboplatin AUC=6 every 3 weeks for six cycles)
Number of subjects: 250
Study 33664127 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant concurrent chemoradiotherapy (whole pelvis irradiation 50.4 Gy and cisplatin 40 mg/m2/week)
Number of subjects: 250
Study 32951642 — intervention group
Group type: EXPERIMENTAL
Intervention: TEDR repair for tears >3 cm
Number of subjects: 80
Study 32951642 — intervention group
Group type: COMPARATOR
Intervention: SR repair for tears >3 cm
Number of subjects: 80
Study 32951642 — intervention group
Group type: EXPERIMENTAL
Intervention: SR repair for tears <3 cm
Number of subjects: 80
Study 32951642 — intervention group
Group type: COMPARATOR
Intervention: TEDR repair for tears <3 cm
Number of subjects: 80
Study 35631319 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial diet
Number of subjects: 37
Study 35631319 — intervention group
Group type: COMPARATOR
Intervention: MUFA diet
Number of subjects: 37
Study 34237597 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT)
Number of subjects: 17
Study 34237597 — intervention group
Group type: COMPARATOR
Intervention: Non-Daikenchuto (non-DKT)
Number of subjects: 17
Study 33551282 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation
Number of subjects: 1232
Study 33551282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1232
Study 34749319 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity magnetic laser therapy (LLLT)
Number of subjects: 154
Study 34749319 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal magnetic stimulation
Number of subjects: 154
Study 34749319 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only
Number of subjects: 154
Study 33683381 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic reconstruction with postoperative infection
Number of subjects: 18
Study 33683381 — intervention group
Group type: COMPARATOR
Intervention: Pelvic fracture fixation (control group)
Number of subjects: 18
Study 34682668 — intervention group
Group type: EXPERIMENTAL
Intervention: E-Fit (home-based exercise intervention)
Number of subjects: 40
Study 32666240 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking Compression Plate (LCP) fixation (group 1)
Number of subjects: 63
Study 32666240 — intervention group
Group type: COMPARATOR
Intervention: Interlocking Nail (ILN) (group 2)
Number of subjects: 63
Study 34115544 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic ALK amplification (ALKa)
Number of subjects: 1092
Study 34115544 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal ALK mutations (ALKm)
Number of subjects: 1092
Study 34115544 — intervention group
Group type: EXPERIMENTAL
Intervention: Subclonal ALK mutations (ALKm)
Number of subjects: 1092
Study 34115544 — intervention group
Group type: EXPERIMENTAL
Intervention: No ALK alterations
Number of subjects: 1092
Study 34115544 — intervention group
Group type: EXPERIMENTAL
Intervention: More than one metastatic compartment
Number of subjects: 1092
Study 32999058 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based motor training telerehabilitation (TR)
Number of subjects: 52
Study 32999058 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR)
Number of subjects: 52
Study 33753870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigil-1st (Vigil first)
Number of subjects: 24
Study 33753870 — intervention group
Group type: COMPARATOR
Intervention: Atezo-1st (Atezolizumab first)
Number of subjects: 24
Study 33753870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigil-1st
Number of subjects: 24
Study 33753870 — intervention group
Group type: COMPARATOR
Intervention: Atezo-1st
Number of subjects: 24
Study 33753870 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigil-1st (in BRCAwt subset)
Number of subjects: 24
Study 33753870 — intervention group
Group type: COMPARATOR
Intervention: Atezo-1st (in BRCAwt subset)
Number of subjects: 24
Study 33549606 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 42
Study 33549606 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 42
Study 35011083 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of WHS
Number of subjects: 93
Study 35011083 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 93
Study 34914845 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivorship Sleep Program (SSP) - 4 weekly sessions
Number of subjects: 40
Study 34914845 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) - CBT-I referral plus sleep hygiene handout
Number of subjects: 40
Study 32338543 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach bias modification (six sessions)
Number of subjects: 40
Study 32338543 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 40
Study 33570130 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative control outcomes in Mendelian randomization studies
Number of subjects: 0
Study 33570130 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative control outcomes in MR studies
Number of subjects: 0
Study 32464838 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracotomy
Number of subjects: 11185
Study 32464838 — intervention group
Group type: COMPARATOR
Intervention: Sternotomy
Number of subjects: 11185
Study 34103434 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombodynamics test in addition to local coagulation tests (LCT)
Number of subjects: 245
Study 34103434 — intervention group
Group type: COMPARATOR
Intervention: Local coagulation tests (LCT)
Number of subjects: 245
Study 35090365 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 52
Study 35090365 — intervention group
Group type: COMPARATOR
Intervention: Physical Education (PE)
Number of subjects: 52
Study 35090365 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 52
Study 32873406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hong Kong strain vaccine
Number of subjects: 100
Study 32873406 — intervention group
Group type: EXPERIMENTAL
Intervention: Saitama strain vaccine
Number of subjects: 100
Study 32873406 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines against A/Osaka/188/2017
Number of subjects: 100
Study 35606707 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-step transepithelial photorefractive keratectomy (TPRK)
Number of subjects: 32
Study 35606707 — intervention group
Group type: COMPARATOR
Intervention: Off-flap epipolis-laser in situ keratomileusis (Epi-LASIK)
Number of subjects: 32
Study 32994091 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant metformin
Number of subjects: 486
Study 32994091 — intervention group
Group type: COMPARATOR
Intervention: No concomitant metformin
Number of subjects: 486
Study 32994091 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant sulfonamide-based α1-receptor blockers
Number of subjects: 486
Study 32994091 — intervention group
Group type: COMPARATOR
Intervention: No concomitant sulfonamide-based α1-receptor blockers
Number of subjects: 486
Study 32994091 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant quinazoline-based α1-receptor blockers
Number of subjects: 486
Study 32994091 — intervention group
Group type: EXPERIMENTAL
Intervention: All other medication classes
Number of subjects: 486
Study 34529913 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% H2O2 for gargling, 0.5% H2O2 for nasal wash (experimental group)
Number of subjects: 100
Study 34529913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment mentioned)
Number of subjects: 100
Study 34743666 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to dolutegravir 50 mg once daily for 120 days
Number of subjects: 20
Study 34743666 — intervention group
Group type: COMPARATOR
Intervention: Remain on raltegravir 400 mg twice daily
Number of subjects: 20
Study 34743666 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 32998932 — intervention group
Group type: EXPERIMENTAL
Intervention: Single postoperative dose of zoledronic acid
Number of subjects: 1000
Study 32998932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 35321778 — intervention group
Group type: EXPERIMENTAL
Intervention: tACS (0.75 mA, 0.75 Hz, 5-minute)
Number of subjects: 9
Study 35321778 — intervention group
Group type: COMPARATOR
Intervention: Control (no tACS)
Number of subjects: 9
Study 33340259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness and compassion program (MAC-P)
Number of subjects: 18
Study 32423006 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-group (serious game intervention)
Number of subjects: 14
Study 32423006 — intervention group
Group type: COMPARATOR
Intervention: Non-game-group (control)
Number of subjects: 14
Study 34662180 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Number of subjects: 191
Study 34662180 — intervention group
Group type: COMPARATOR
Intervention: CISGEM
Number of subjects: 191
Study 34963666 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video intervention
Number of subjects: 79
Study 34963666 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 79
Study 35678882 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrosomial iron supplementation (30 mg daily for 12 weeks)
Number of subjects: 60
Study 35678882 — intervention group
Group type: COMPARATOR
Intervention: No supplementation to ESA treatment (Control group)
Number of subjects: 60
Study 32179149 — intervention group
Group type: EXPERIMENTAL
Intervention: Colistin loading dose (LD group) of 4 mg of colistin base activity (CBA)/kg/dose
Number of subjects: 20
Study 32179149 — intervention group
Group type: COMPARATOR
Intervention: Standard initial dose (NLD group) of 2.5 mg (12‐h interval) or 1.7 mg (8‐h interval) of CBA/kg/dose
Number of subjects: 20